Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.98 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.98 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.98 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.98 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.78 |
| ▸ | KARS1 | Q15046 | 3/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | RXRA | P19793 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14029315 | 0.99 | CYP3A4 (1.00) | CYP3A4MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL29380336 | 0.99 | CYP3A4 (1.00) | CYP3A4MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL31682257 | 0.99 | CYP3A4 (1.00) | CYP3A4MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL27863 | 0.99 | CYP3A4 (1.00) | CYP3A4MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL4943352 | 0.99 | CYP3A4 (1.00) | CYP3A4MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL9108470 | 0.99 | CYP3A4 (1.00) | CYP3A4MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL27864 | 0.99 | CYP3A4 (1.00) | CYP3A4MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL17158674 | 0.99 | CYP3A4 (1.00) | CYP3A4MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL5933820 | 0.98 | CYP3A4 (0.98) | CYP3A4MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL17453400 | 0.98 | CYP3A4 (0.98) | CYP3A4MEN1KMT2ATSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024173715-A1 | ANTIFUNGAL COMPOSITIONS AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-08-22 | — | — | WO | claimed |
| WO-2024254159-A1 | COMPOSITIONS AND METHOD FOR DIAGNOSING AND TREATING ALZHEIMER'S DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024173715-A1 | ANTIFUNGAL COMPOSITIONS AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-08-22 | — | — | WO | disclosed |
| US-11986489-B2 | Method of treating a disease using a glycolytic dependent compound | ETHICON, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| EP-3334471-B1 | IMPROVED CANCER TREATMENT WITH DOXORUBICIN | ETHICON INC (US) | 2023-06-21 | — | — | EP | disclosed |
| US-20220348876-A1 | METABOLISM GUIDES DEFINITIVE LINEAGE SPECIFICATION DURING ENDOTHELIAL TO HEMATOPOIETIC TRANSITION | AMNIOTICS AB (SE) | 2022-11-03 | — | — | US | disclosed |
| EP-4065694-A1 | METABOLISM GUIDES DEFINITIVE LINEAGE SPECIFICATION DURING ENDOTHELIAL TO HEMATOPOIETIC TRANSITION | Amniotics AB (SE) | 2022-10-05 | — | — | EP | disclosed |
| CN-114981412-A | Metabolic guided permanent lineage specification during endothelial cell to hematopoietic cell transition | AMNIOTICS公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20220054527-A1 | METHOD OF TREATING A DISEASE USING A GLYCOLYTIC DEPENDENT COMPOUND | OMRIX BIOPHARMACEUTICALS LTD. (IL) | 2022-02-24 | — | — | US | disclosed |